[Various aspects of immunomodulating therapy in patients with protracted pneumonia during convalescence].
D000276:Adjuvants, Immunologic; D000293:Adolescent; D000328:Adult; D001402:B-Lymphocytes / Q000276:immunology; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D003289:Convalescence; D004338:Drug Combinations / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004963:Estrenes / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008231:Lymphopenia / Q000188:drug therapy* / Q000378:metabolism; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage*; D011354:Prodigiozan / Q000008:administration & dosage*; D013450:Sulfones / Q000008:administration & dosage*; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014131:Trace Elements / Q000097:blood; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000276:Adjuvants, Immunologic; D001559:Benzhydryl Compounds; D004338:Drug Combinations; D004963:Estrenes; D011135:Polysaccharides, Bacterial; D013450:Sulfones; D014131:Trace Elements; C023367:diucifon; D014498:Uracil; C034533:bolandiol dipropionate; D011354:Prodigiozan; C016914:flumecinol
Nekotorye aspekty immunomoduliruiushcheĭ terapii bol'nykh zatiazhnoĭ pnevmonieĭ v periode rekonvalestsentsii.